Infantile Autism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for infantile autism. 324 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
324
Active US patents
59/100
Avg vulnerability
$3.0B
Annual revenue covered

Originators in Infantile Autism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Johnson & Johnson (Janssen) 110 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating infantile autism. Each bar = one year. Y-axis scaled to peak year (54 patents).

28
26
35
27
18
28
54
29
48
30
40
31
26
32
40
33
8
34
17
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Risperdal
risperidone
 Johnson & Johnson (Janssen) 110 56 — 2026-06-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
9125939 Abilify method of use 80 2026-07-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9023897 Risperdal formulation 33 2033-04-05
9180197 Risperdal formulation 38 2028-02-13
10010612 Risperdal formulation 38 2028-02-13
9180197 Risperdal formulation 38 2028-02-13

Related